PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Meeting Abstract
| Authors: | Liu, M. C.; Pitcher, B. N.; Mardis, E. R.; Davies, S. R.; Snider, J. E.; Vickery, T.; Reed, J. P.; DeSchryver, K.; Singh, B.; Friedman, P. N.; Gradishar, W. J.; Perez, E. A.; Martino, S.; Citron, M. L.; Norton, L.; Winer, E. P.; Hudis, C. A.; Perou, C. M.; Ellis, M. J.; Barry, W. T. |
| Abstract Title: | PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy |
| Meeting Title: | 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 72 |
| Issue: | 24 Suppl. |
| Meeting Dates: | 2012 Dec 4-8 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2012-12-15 |
| Language: | English |
| ACCESSION: | WOS:000209704900204 |
| DOI: | 10.1158/0008-5472.sabcs12-p2-10-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P2-10-01 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
